
European Energy scales up its business in an extraordinary 2022
Company announcement 4/2023 (28.02.2023)
The annual result for 2022 shows a growth of more than 60% on key financial figures and a fivefold increase of new connected energy to the grid.
European Energy has released its annual report for 2022. The key financials show a growth of EBITDA from EUR 81m to EUR 135m and profit before tax from EUR 63m to EUR 110m. The profit before tax for the year, meets the upper range target of the outlook which was EUR 100m +/- 10%, while EBITDA met the exact target on EUR 135m.
The growth in the company has come despite unpredictable market conditions. With the volatility in the market, price forecasting on logistics and components has been close to impossible. However, power prices have remained high across the markets where European Energy produces electricity, which is reflected in the result.
The building program of European Energy has seen a significant growth during 2022. European Energy invested nearly EUR 800m in the green transition in 2022. The company also connected 655 MW in 2022 – almost five times higher than in 2021. In total, European Energy had more than 1.3 GW of renewable energy capacity under construction at year-end 2022 compared to 0.8 GW in 2021.
The number of employees expanded to 550 by the end of 2022 from 343 by the end of 2021. This growth was reflected across the company as a whole with a large share of new employees being hired in local markets. The geographical spread of European Energy also reflects in the number of offices that the company has across the world. In total eight new local offices were opened in 2022 bringing the total number of offices up to 23 in 18 different countries.
Power-to-X is an area where European Energy expects to have significant progress in 2023. The company has been at the forefront of the development in this area. With the expected production of both green hydrogen as well as e-methanol in 2023, European Energy has in a few years established itself as a significant developer in the Power-to-X space which is underlined by the partnerships that have been established with tier 1-shipping companies such as Maersk and HMM.
For 2023, European Energy expects significant growth across all parameters. However, there are factors that have an adverse effect including increased financial market volatility, regulatory responses as well as delays in permits or supply chains. Taken these risk factors into account, European Energy expect an EBITDA of EUR 180m and a profit before tax of EUR 140m for 2023. We assess that the aforementioned increased risks and volatility could impact realized results by a margin of +/- 20% compared to outlook.
Annual report: https://europeanenergy.com/wp-content/uploads/2023/02/annualreport2022.pdf
ESG report: https://europeanenergy.com/wp-content/uploads/2023/02/esgreport2022.pdf
For further information, please contact Investor Relations: investor.relations@europeanenergy.com.
This announcement has been made in accordance with the market abuse regulation (regulation (EU) no. 596/2014 on market abuse).
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CFO Martin Klöti to leave Schweiter Technologies29.3.2023 06:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR CFO Martin Klöti to leave Schweiter Technologies Martin Klöti, Chief Financial Officer (CFO) and member of the Management of Schweiter Technologies, has decided to leave the company Steinhausen, 29 March 2023 – Martin Klöti, who has been with Schweiter Technologies since 2003 and CFO of the Group since 2014, has decided to leave the Management as of September 2023 to take up a new position outside the company. The Board of Directors will be sorry to see him leave and wishes to take this opportunity to thank him for his many years of dedicated service and his enormous contribution to the development of Schweiter Technologies. The search for his successor will be initiated forthwith. For further information please contact: Martin Klöti, CFO Tel. +41 41 757 77 00 investor@schweiter.com ABOUT SCHWEITER Schweiter Technologies, with its head office in Steinhausen, Switzerland, is a globally active Group focusing on composites solutions with its divi
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia29.3.2023 05:39:38 CEST | Press release
-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the development, medical affairs, production of finished products, and commercialization of toripalimab within the cooperation territory. The profits available for distribution by Excellmab will be distributed in proportion to the respective shareholdings of the parties -- Using the Excellmab platform, the two parties also plan to collaborate extensively to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development -- According to the progress of toripalimab’s R&D and other projects, Junshi Biosciences may receive a milestone payment of up to approximately US$4.52 million, plus a certain percentage of royalties on net sales SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Bioscience
Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor
Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release
Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at www.banken.gl. The minutes of the Annual General Meeting will also be pub